Iodine (125I) CC49
Iodine (125I) CC49 is an iodine-125 radiolabelled monoclonal antibody for the detection of tumours. It is used in radioimmunoassays like CA 72-4.[1]
CC49 has also been tested for the treatment of solid tumours, but without success. Iodine (131I) CC49 and lutetium (177Lu) CC49, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in Phase I and II trials.[2]
Derivatives
A wide range of CC49 derivatives has been used in pharmaceutical research. Examples include chimeric[2] and humanized CC49[3], as well as a fusion protein of a CC49 single-chain variable fragment and the enzyme beta-lactamase.[4]
References
- ^ Guadagni, F.; Roselli, M.; Cosimelli, M.; Spila, A.; Cavaliere, F.; Tedesco, M.; Arcuri, R.; Abbolito, M. R. et al. (1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer research 56 (22): 5293–5298. PMID 8912871. edit
- ^ a b Trahan Rieger, Paula, ed (2001). Biotherapy (2nd ed.). Jones and Bartlett. pp. 334–335. ISBN 0-7637-1428-3.
- ^ Milenic, D. E.; Brady, E. D.; Garmestani, K.; Albert, P. S.; Abdulla, A.; Brechbiel, M. W. (2010). "Improved efficacy of α-particle-targeted radiation therapy". Cancer 116 (4 Suppl): 1059–1066. doi:10.1002/cncr.24793. PMID 20127951. edit
- ^ Alderson, R. F.; Toki, B. E.; Roberge, M.; Geng, W.; Basler, J.; Chin, R.; Liu, A.; Ueda, R. et al. (2006). "Characterization of a CC49-Based Single-Chain Fragment−β-Lactamase Fusion Protein for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)". Bioconjugate Chemistry 17 (2): 410–418. doi:10.1021/bc0503521. PMID 16536473. edit
|
|
|
| Tumor ("-t(u[m])-") |
|
Human ("-tumu-")
|
|
|
|
Mouse ("-tumo-")
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|